Part 2: Statistical Programming & Compliance We sat down with the instructors for MMS Academy, MMS’ learning arm, for some advice on how to be successful to help those looking to work in the pharma industry. In our first article, we talked with our instructors for...
MMS Holdings Expert Insights Blog
Experts at MMS share their insights on trending
topics in the pharmaceutical industry.
How to Succeed in the Pharma Industry: Conversations with Instructors at MMS Academy Part 1
Part 1: Medical Writing and Pharmacovigilance We sat down with the instructors for MMS Academy, MMS’ learning arm, for some advice on how to be successful to help those looking to work in the pharma industry. In this first article, we talked with our instructors for...
How to Get an FDA Orphan Drug Designation
The Orphan Drug Act provides incentives to sponsors to promote the development of drugs for the prevention, diagnoses, and treatment of rare diseases or conditions that affect fewer than 200,000 individuals in the United States, and for which the sponsor is not...
FDA’s Recent Benefit Risk Assessment Guidance Explained: What It Means for Sponsors
In September 2021, the Food and Drug Administration (FDA) released its Benefit-Risk Assessment Guidance as part of the Prescription Drug User Fee Amendments (PDUFA) VI Implementation Plan which covers 2018 through 2022. PDUFA VI focuses on integrating patient...
New FDA Guidance to Support Ultra-Rare Disease Drug Development
Antisense oligonucleotide (ASO) drug products target a specific sense mRNA to modulate gene expression in living cells and have been used successfully to treat diseases where the pathogenic mutation has been identified. For patients with an...
Looking back at 2021 – MMS Holdings year in review
2021 brought more challenges and opportunities than ever before. From the starts and stops of opening workplaces, schools and economies to managing an overflowing email inbox, it can be challenging to keep up with all the information you need. So, we rounded up...
FDA Expedited Program Designations to Support Rare Disease Drug Development
One in 10 Americans is affected by rare diseases—more than half of which are children—and approximately 95% of the more than 7,000 rare diseases have no available treatments. To advance the development of rare disease treatments, the Food and Drug Administration...
Second Annual Global Champions of Change Competition Winner
MMS has just concluded its second annual Global Champions of Change Competition (G3C), where colleagues from all MMS regions submitted innovative ideas based on our tradition of providing high-quality, efficient services to our clients to help discover and market...
How to use a Master Protocol to gain Efficiencies in a Clinical Trial
The clinical development industry is an ever-changing field. It’s crucial to stay ahead of industry changes and ensure compliance with the needs of health authorities. Experienced medical writers understand the purpose of a trial and work closely with the study team...